Neulasta is an injection that boosts your white blood cell count after chemotherapy. Chemotherapy attacks fast-growing cells, which includes cancer cells but also the infection-fighting white blood cells your bone marrow produces. That leaves you vulnerable to serious infections during the days after treatment. Neulasta works by stimulating your bone marrow to produce, mature, and release more of these cells, specifically a type called neutrophils, which are your body’s first responders against bacteria and other pathogens.
How Neulasta Works in Your Body
Neulasta is a long-acting form of a protein that mimics a natural growth factor in your body. It signals your bone marrow to ramp up production of neutrophils and also helps the neutrophils that already exist survive longer. The “long-acting” part matters: a chemical modification keeps the drug circulating in your bloodstream for days instead of hours, so you only need one injection per chemotherapy cycle rather than daily shots.
The effect is fast. White blood cell counts typically spike within one to two days after the injection. In some patients, counts climb high enough to be considered an “overshoot,” exceeding 30,000 cells per cubic millimeter in roughly 30% of cases. This surge is temporary and generally resolves on its own as your body self-regulates.
Why It’s Prescribed During Chemotherapy
The specific problem Neulasta prevents is called febrile neutropenia, a dangerous combination of very low white blood cell counts and fever that signals your body can’t fight off infection. This is one of the most common reasons chemotherapy patients end up hospitalized, and it can delay future treatment cycles.
In clinical trials, the difference was stark. Among patients on chemotherapy regimens known to suppress white blood cells, only 1% of those who received Neulasta developed febrile neutropenia compared to 17% of those who received a placebo. Hospitalization rates dropped from 14% to 1%, and the need for intravenous antibiotics fell from 10% to 2%. Neulasta is approved for patients with non-blood cancers (solid tumors and similar malignancies) who are receiving chemotherapy likely to cause significant drops in white blood cell counts.
How and When You Receive It
The standard dose is a single 6 mg injection given once per chemotherapy cycle. It’s delivered as a shot under the skin, typically in the upper arm or abdomen. Timing matters: the injection is given at least 24 hours after chemotherapy ends, and there should be at least 12 days between the Neulasta dose and your next chemotherapy cycle. This spacing ensures the drug stimulates new cell growth without interfering with chemotherapy’s intended effects.
There are two ways to receive the injection. The first is a standard prefilled syringe, administered by a healthcare provider the day after your chemotherapy session. The second is the Onpro on-body injector, a small, lightweight, battery-powered device that a provider attaches to your skin (usually your abdomen) on the same day as chemotherapy. It’s programmed to automatically deliver the dose about 27 hours later, so you don’t need to return to the clinic the next day. The injection itself takes about 45 minutes to complete, and the device is waterproof. Once it finishes, you remove it and dispose of it.
Bone Pain and Other Common Side Effects
Bone pain is the side effect most closely linked to Neulasta itself, and it’s common. In clinical trials, about 26% of patients reported bone pain that was attributed to the drug, with skeletal pain, back pain, and limb pain being the most frequent types. This makes biological sense: the medication is pushing your bone marrow into overdrive, and that increased activity can cause aching or soreness in the bones of your pelvis, sternum, and long bones. For most people the pain is mild to moderate. Severe bone pain occurred in about 3% of patients at the standard dose.
Many other side effects reported in trials, like nausea (72%), fatigue (70%), hair loss (69%), and diarrhea (49%), overlap heavily with the effects of chemotherapy itself, making it difficult to separate which drug is responsible. Joint pain (20%), muscle pain (22%), and headache (25%) were also frequently reported and may be partially related to the immune system ramping back up.
Over-the-counter pain relievers like ibuprofen or acetaminophen are commonly used to manage bone pain from Neulasta. Some patients also find that antihistamines like loratadine help, though this is based on clinical experience rather than large trials.
Rare but Serious Risks
Two uncommon complications are worth knowing about because they require immediate medical attention.
The first is splenic rupture. Because the spleen filters blood cells and can enlarge when white blood cell production surges, there is a small risk of the spleen rupturing. Warning signs include pain in your left upper abdomen or left shoulder tip. This is rare but considered a medical emergency.
The second is capillary leak syndrome, a condition where fluid leaks out of small blood vessels into surrounding tissue. Symptoms include sudden swelling (especially in the limbs), rapid weight gain, feeling faint or lightheaded, and difficulty breathing. In published cases, low blood pressure and widespread edema were the most common presentations. This complication is also rare but can become serious quickly if not treated.
Biosimilar Alternatives
Neulasta was the original brand, but several biosimilar versions are now available. Biosimilars are near-identical copies of biologic drugs that have been tested and approved to work the same way. Options include products sold under names like Fulphila, Udenyca, Ziextenzo, Nyvepria, Fylnetra, and Stimufend. All contain the same active ingredient at the same dose. Your insurance plan may prefer one over another, and in some cases, your provider may need to try a shorter-acting version first before moving to a long-acting option like Neulasta or its biosimilars. Functionally, the experience for you as a patient is the same regardless of which version you receive.